Myringoplasty for Eosinophilic Otitis Media.
Journal
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
ISSN: 1537-4505
Titre abrégé: Otol Neurotol
Pays: United States
ID NLM: 100961504
Informations de publication
Date de publication:
01 07 2023
01 07 2023
Historique:
medline:
16
6
2023
pubmed:
26
5
2023
entrez:
25
5
2023
Statut:
ppublish
Résumé
Surgical intervention of eosinophilic otitis media (EOM) has been considered contraindicated because middle ear surgery is associated with a risk of deafness. Myringoplasty is believed to be less invasive. Therefore, we analyzed the surgical results of myringoplasty for perforated eardrums in patients with EOM treated by biological drugs (biologics). Retrospective chart review. Tertiary referral center. Nine ears of seven patients with EOM with eardrum perforation associated with bronchial asthma were treated with add-on biologics; myringoplasty was then performed. The controls comprised 17 ears of 11 patients with EOM treated by myringoplasty without biologics. The EOM status of each patient of both groups was assessed using severity scores, hearing acuity, and temporal bone computed tomography scores. Preoperative and postoperative changes in severity scores and hearing acuity, postoperative closure of the perforation, and relapse of EOM. Severity scores significantly decreased after the use of biologics but did not change after myringoplasty. One patient developed postoperative relapse of middle ear effusion (MEE); in the control group, however, 10 ears developed recurrence of MEE. Significant improvement of the air conduction hearing level was obtained in the biologics group. No patients showed deterioration of the bone conduction hearing level. This is the first report to describe successful surgical interventions with add-on biologics for patients with EOM. In the era of biologics, surgical interventions such as myringoplasty will be indicated to improve hearing and to avoid recurrence of MEE in patients with EOM with perforated eardrums, with the use of biologics.
Identifiants
pubmed: 37231536
doi: 10.1097/MAO.0000000000003904
pii: 00129492-202307000-00011
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
572-577Informations de copyright
Copyright © 2023, Otology & Neurotology, Inc.
Déclaration de conflit d'intérêts
Disclosure statement: The authors declare no conflicts of interest.
Références
Tomioka S, Kobayashi T, Takasaka T. Intractable otitis media in patients with bronchial asthma (eosinophilic otitis media). In: Sanna M, ed. Cholesteatoma and Mastoid Surgery . Rome: CIC Edizioni Internazionali; 1997:851–3.
Iino Y, Tomioka-Matsutani S, Matsubara A, Nakagawa T, Nonaka M. Diagnostic criteria of eosinophilic otitis media, a newly recognized middle ear disease. Auris Nasus Larynx 2011;38:456–61.
Suzuki H, Matsutani S, Kawase T, et al. Epidemiologic surveillance of “eosinophilic otitis media” in Japan. Otol Jpn 2004;14:112–7 (Abstract in English).
Esu Y, Tamii S, Masuda M, Iino Y, Yoshida Y. Effectiveness of myringoplasty in patients with eosinophilic otitis media. Auris Nasus Larynx 2021;48:368–76.
Iino Y, Hara M, Hasegawa M, et al. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media. Otol Neurotol 2012;33:1218–24.
Iino Y, Takahashi E, Ida S, Kikuchi S. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media. Auris Nasus Larynx 2019;46:196–203.
Suzaki I, Kimura Y, Tanaka A, et al. Successful treatment of eosinophilic otitis media associated with bronchial asthma with an anti-IL5 monoclonal antibody, mepolizumab. Auris Nasus Larynx 2019;46:141–6.
Chow K, Cosetti MK. Use of IL-5 inhibitor benralizumab as a novel therapy for eosinophilic otitis media: clinical capsule and review of literature. Otol Neurotol 2020;41:e238–40.
Iino Y, Sekine Y, Yoshida S, Kikuchi S. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma. Auris Nasus Larynx 2021;48:353–60.
Iino Y, Nagamine H, Kakizaki K, et al. Effectiveness of instillation of triamcinolone acetonide into middle ear for eosinophilic otitis media associated with bronchial asthma. Ann Allergy Asthma Immunol 2006;97:761–6.
Yuasa R, Yuasa Y. Postoperative results of simple underlay myringoplasty in better hearing ear. Acta Otolaryngol 2008;128:139–43.
Lund VJ, Kennedy DW. Staging for rhinosinusitis. Otolaryngol Head Neck Surg 1997;117(Suppl):S35–40.
Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant 2013;48:452–8.
Banno T, Inagawa S, Matsumoto N, Inafuku S. Investigation of eosinophilic otitis media [Kousankyuuseichuujiensyourei no kentou]. Gendaiigaku 2002;49:381–9.
Sakuma Y, Ishitoya J, Hirama M. A case of efficient treatment with omalizumab (anti-IgE antibodies) for eosinophilic otitis media. Otol Jpn 2013;23:98–104 (Abstract in English).
Yazawa Y. Long-term course of eosinophilic otitis media [Kousankyuuseichuujien no choukikeika]. ENOTNI 2004;34:27–32.
Matsubara A, Nishizawa H, Kurose A, et al. An experimental study of inner ear injury in an animal model of eosinophilic otitis media. Acta Oto-Laryngolgica 2014;134:227–32.
Kikuchi S, Yoshida S, Sugiyama T, Iino Y. A case of eosinophilic otitis media successfully treated by tympanoplasty with use of dupilumab. Otolaryngolgy Case Reports 2021;21:100381.
Nonaka M, Fukumoto A, Ozu C, et al. IL-5 and eotaxin levels in middle ear effusion and blood from asthmatics with otitis media with effusion. Acta Otolaryngol 2003;123:383–7.
Iino Y, Kakizaki K, Katano H, Saigusa H, Kanegasaki S. Eosinophil chemoattractant in middle ear of patients with eosinophilic otitis media. Clin Exp Allergy 2005;35:1370–6.
Iino Y, Kakizaki K, Saruya S, et al. Eustachian tube function in patients with eosinophilic otitis media. Arch Otolaryngol Head Neck Surg 2006;132:1109–14.